Back to catalogue
GENF

Genflow Biosciences PLC

Health Care First-pass screen £15m
330/1000 Overall fit
AI beneficiary 35% 33
Operating leverage 25% 33
Valuation 25% 29
Downside protection 15% 39

First-pass take

Pre-clinical SIRT6 gene therapy company with minor AI partnership (Heureka Labs) supporting internal drug design—not core strategy or revenue driver. £1.4m annual burn against £111k cash; dependent on non-dilutive Wallonia grants and future capital raises. Platform transition to mRNA/LNP is scientifically sound but commercial success remains highly speculative.

Flags

pre-clinicalpre-revenueloss-makingcash-burnfunding-dependentlicense-dependentdevelopment-stage